Compare ICUI & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICUI | RLAY |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 1995 | 2020 |
| Metric | ICUI | RLAY |
|---|---|---|
| Price | $158.16 | $18.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $169.00 | $19.50 |
| AVG Volume (30 Days) | 269.5K | ★ 3.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.62 | 31.78 |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $2,231,262,000.00 | $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.46 | $324.03 |
| P/E Ratio | $127.88 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $107.02 | $3.03 |
| 52 Week High | $162.85 | $20.79 |
| Indicator | ICUI | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 57.40 |
| Support Level | $139.88 | $18.33 |
| Resistance Level | $161.30 | $20.79 |
| Average True Range (ATR) | 4.52 | 1.14 |
| MACD | -0.84 | -0.22 |
| Stochastic Oscillator | 39.41 | 39.02 |
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.